Ipamorelin vs Tesamorelin: Growth Hormone Two Different Ways

Ipamorelin and tesamorelin get filed together because both end with the pituitary releasing growth hormone. That shared endpoint hides almost everything that matters. They bind different receptors, sit at opposite ends of the evidence spectrum, are dosed at scales that differ by roughly tenfold, and produce different side effect profiles for structural reasons rather than incidental ones.

The comparison is also, in most cases, the wrong frame. These two are not competing for the same slot in a protocol. They occupy adjacent slots, and the interesting question is usually whether you need both rather than which one wins.

The Same Gland, Two Different Doors

Growth hormone release from the anterior pituitary is governed by two opposing signals plus one amplifier. Growth hormone releasing hormone tells the somatotrophs to fire. Somatostatin tells them to stop. Ghrelin, arriving from the gut, both stimulates release and suppresses the somatostatin brake.

Tesamorelin works on the first of those. It is a GHRH analogue, binding the GHRH receptor and pushing the accelerator directly. Ipamorelin works on the third. It is a ghrelin receptor agonist, binding GHS-R1a, which means it pushes its own accelerator and simultaneously eases off the brake.

Why the receptor difference is the whole article

Two compounds that share a receptor compete for it. Two compounds on separate receptors add. This is the reason stacking two GHRH analogues is largely pointless, a problem covered in the tesamorelin and sermorelin comparison, while pairing a GHRH analogue with a ghrelin receptor agonist produces a pulse larger than the sum of the two run separately. Every practical difference below follows from which door each compound uses.

What Tesamorelin Actually Is

Tesamorelin is a synthetic analogue of full length human GHRH(1-44) carrying a trans-3-hexenoyl group on the N-terminal tyrosine. That modification exists for one purpose. Dipeptidyl peptidase-4 cleaves native GHRH between its first two residues within minutes of the molecule entering circulation, and the hexenoyl group physically obstructs that site.

The result is a circulating half-life closer to half an hour after subcutaneous injection, against a handful of minutes for unmodified GHRH. Longer receptor occupancy means the somatotrophs release across a wider window before somatostatin closes things down, and that is the mechanistic reason tesamorelin produces the larger IGF-1 response of the two compounds on this page.

It is also the only one with an approval. Tesamorelin was cleared in 2010 under the brand name Egrifta for the reduction of excess visceral adipose tissue in people with HIV-associated lipodystrophy. Two phase 3 trials at 2mg daily for 26 weeks produced roughly a 15 percent reduction in visceral fat against a small increase on placebo. A 52 week extension showed the reduction held while dosing continued and regressed toward baseline in participants taken off it. The full profile sits in the tesamorelin peptide guide.

What Ipamorelin Actually Is

Ipamorelin is a pentapeptide, five residues against tesamorelin's forty-four. It belongs to the growth hormone releasing peptide family, and its selling point within that family is selectivity.

The older ghrelin receptor agonists are not clean. GHRP-6 and hexarelin raise cortisol, ACTH and prolactin alongside growth hormone at doses in the normal working range, and GHRP-6 in particular produces hunger strong enough to be a dosing problem rather than a side note. Ipamorelin was designed to strip that out. In the published preclinical and early human work it releases growth hormone with minimal movement in cortisol and prolactin, and with far weaker appetite stimulation than GHRP-6. The ipamorelin guide covers that selectivity data in more depth, and the GHRP-6 comparison shows what the older profile looks like by contrast.

What ipamorelin does not have is an approval or a body composition trial. Novo Nordisk developed it, but for postoperative ileus rather than for anything a peptide user cares about, and that program was discontinued when the trials missed their endpoints. The absence of approval reflects where the development money went, not a safety signal.

Side by Side

The Evidence Is Not Symmetrical

This is the part that gets flattened in most side by side posts. Tesamorelin has a quantified effect on a hard endpoint, measured by imaging, in a controlled population, with a follow-up period. Ipamorelin has pharmacokinetics, receptor selectivity data and a discontinued program aimed at something else entirely.

That asymmetry does not make ipamorelin ineffective. It does mean any claim about what ipamorelin does to body composition in healthy adults is an inference from growth hormone release rather than a measured outcome. Anyone presenting the two as equally evidenced is not reading the same literature.

It cuts the other way on generalisability. Tesamorelin's data comes from one specific patient population with a specific fat distribution problem. Extrapolating a 15 percent visceral fat reduction from that group to a healthy adult with ordinary body composition is its own leap. Good data in a narrow population is not the same as good data in yours.

Side Effects Diverge for Structural Reasons

Tesamorelin's adverse effect profile is the one you would predict from sustained GHRH signalling. Injection site reactions are the most common. Beyond that, the trials reported joint pain, peripheral oedema, muscle aches and the fluid retention effects that follow any meaningful rise in IGF-1. Glucose tolerance drifts in the wrong direction for some participants, which matters more the longer the course runs.

Ipamorelin's profile is shaped by its ghrelin receptor activity and by what that activity does not do. Transient flushing or head rush shortly after administration is the common report. Water retention and mild lethargy show up at higher doses. Because the compound is selective, the cortisol and prolactin problems that dog GHRP-6 largely do not appear, and appetite stimulation is modest rather than disruptive. The broader picture sits in the peptide side effects overview.

Both share the baseline caution that applies to anything raising IGF-1, which is that growth signalling is not selective about what it acts on.

Dosing Scale Is the Practical Hazard

Tesamorelin was trialled at 2mg daily, injected subcutaneously in the abdomen, typically in the evening to sit alongside the natural nocturnal growth hormone pulse. Ipamorelin works in the microgram range, commonly cited around 200 to 300mcg per administration, sometimes split across two or three doses.

That is close to a tenfold gap in scale, and it is the single most common source of serious error when someone runs both. Reconstitution volumes, syringe markings and mental arithmetic all carry over from one vial to the next, and a habit formed on a milligram compound produces an order of magnitude mistake when applied to a microgram one. The ipamorelin dosage guide and the tesamorelin dosage guide handle each separately for exactly this reason, and the reconstitution guide covers the arithmetic itself.

Why This Is Usually the Wrong Question

The standard advanced approach is not to pick one. A GHRH analogue plus a ghrelin receptor agonist hits two receptors, the signals add, and the somatostatin suppression from the GHRP side means more of the GHRH signal survives to the pituitary. The pairing is the reason the tesamorelin and ipamorelin stack exists as a protocol at all, and the same logic drives the more common and far cheaper CJC-1295 and ipamorelin combination.

Cost is what usually decides between those two pairings. Tesamorelin carries brand pricing that runs into thousands of dollars a month through legitimate channels, and its approval covers one narrow population. CJC-1295 delivers a GHRH signal at a fraction of the price, which is why it, rather than tesamorelin, is the GHRH half of most real protocols. Tesamorelin earns its price only when visceral fat specifically is the target and the trial data is the reason for choosing it.

If neither is obviously right, the comparison sitting one step earlier is ipamorelin against sermorelin, which is the same receptor argument at a lower price point.

The Research Chemical Caveat

Every number on this page comes from studies run with pharmaceutical grade material at verified concentrations under supervision. None of those conditions hold for material bought online, and two failure modes sit entirely outside the data above.

Concentration error is the first, and the tenfold dosing gap between these two compounds makes it unusually dangerous here. Purity is the second, and it is unverifiable without a batch certificate of analysis. Storage handling compounds both, because a degraded vial presents as an ineffective compound rather than a spoiled one, and the usual response to an ineffective compound is to increase the dose.

Frequently Asked Questions

Is ipamorelin or tesamorelin stronger?

On measured IGF-1 response at label dosing, tesamorelin is the larger signal, and it is the only one of the two with that response quantified in phase 3 trials. Ipamorelin has never been taken through a trial designed to measure body composition, so there is no number to place beside it. Strength is also the wrong axis here, because the two act on different receptors. Running them together produces a bigger pulse than either does alone, which is why the comparison usually resolves into a combination rather than a winner.

Do ipamorelin and tesamorelin work the same way?

No. Tesamorelin binds the GHRH receptor on pituitary somatotrophs. Ipamorelin binds GHS-R1a, the ghrelin receptor, and additionally blunts somatostatin, the brake on growth hormone release. Both end in the pituitary releasing its own growth hormone, but they arrive there through separate pathways, which is the mechanistic reason the two are additive rather than redundant.

Can you take ipamorelin and tesamorelin together?

Mechanistically the pairing is sound, because a GHRH analogue and a ghrelin receptor agonist occupy different receptors and their signals add rather than compete. That logic is well established for GHRH plus GHRP pairings in general. What does not exist is a trial of this specific combination in healthy adults, so the reasoning runs on mechanism and on data from other GHRH and GHRP pairs rather than on direct evidence.

Why does tesamorelin have FDA approval and ipamorelin does not?

Tesamorelin was taken through two phase 3 trials with visceral adipose tissue as a measured endpoint and was approved in 2010 under the brand name Egrifta for excess visceral fat in people with HIV-associated lipodystrophy. Ipamorelin was developed by Novo Nordisk for postoperative ileus rather than for body composition, and that program was discontinued when the trials did not hit their endpoints. The absence of approval reflects a development decision, not a safety finding.

Does ipamorelin raise cortisol or prolactin?

That is the selectivity ipamorelin was designed for. Earlier ghrelin receptor agonists such as GHRP-6 and hexarelin raise cortisol, ACTH and prolactin alongside growth hormone at doses in the usual range. Ipamorelin releases growth hormone with minimal effect on those hormones in the published preclinical and early human work, and it also stimulates appetite far less than GHRP-6 does. Selectivity is the main argument for it over the older compounds.

How different are the doses for ipamorelin and tesamorelin?

By roughly a factor of ten, and this is the practical hazard when someone runs both. Tesamorelin was trialled at 2mg daily, dosed in milligrams. Ipamorelin sits in the microgram range, commonly cited around 200 to 300mcg per administration. A reconstitution habit carried from one vial to the other produces an order of magnitude error rather than a slightly wrong dose, so the two should be calculated separately every time.